Department of Fetomaternal, Faculty of Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran 14155-6559, Iran.
J Genet. 2021;100.
A growing body of evidence demonstrates that the oncogenic miRNAs are critical components that are involved in breast cancer (BC) progression. Thus, they are attracting a great deal of consideration as they provide opportunities for the novel avenues for developing BC targeted therapy. In the current review, we try to discuss the key oncogenic miRNAs implicated in cell migration, invasion and metastasis (e.g., miR-9, miR-10b, miR-10b-5p, miR-17/9, miR-21, miR-103/107, miR-181b-1, miR-301, miR-301a, miR-373, miR- 489, miR-495 and miR-520c), apoptosis inhibition (e.g., miR-21, miR-155, miR-181, miR-182 and miR-221/222), cell proliferation (e.g., miR-221/222, miR-17/92, miR-21, miR-301a, miR-155, miR-181 b, miR-182, miR-214, miR-20b, miR-29a, miR-196, miR-199a-3p, miR- 210, miR-301a, miR-375, miR-378-3p and miR-489), and angiogenesis (e.g., miR-9, miR-17/92 cluster, miR-93 and miR-210). In particular, here, we considered miRNA-based therapeutic approaches to summarize the evidence for their potential therapeutic uses in clinical practice. Therefore, miRNA mimics (i.e., replacement and restoration of miRNAs) and inhibition therapy (e.g., anti-miRNA oligonucleotides (AMO), antagomiRs or antisense oligonucleotides (ASOs): cholesterol-conjugated anti-miRs and locked nucleic acid (LNA)), miRNA sponges, nanoparticles (NPs), multiple-target anti-mirna antisense oligonucleotide technology (MTg-AMOs), and artificial miRNAs (amiRNAs) have been indicated throughout the article as much as possible.
越来越多的证据表明，致癌 miRNA 是参与乳腺癌（BC）进展的关键组成部分。因此，它们作为开发 BC 靶向治疗的新途径提供了机会，引起了广泛关注。在本综述中，我们尝试讨论了涉及细胞迁移、侵袭和转移的关键致癌 miRNA（例如 miR-9、miR-10b、miR-10b-5p、miR-17/9、miR-21、miR-103/107、miR-181b-1、miR-301、miR-301a、miR-373、miR-489、miR-495 和 miR-520c）、凋亡抑制（例如 miR-21、miR-155、miR-181、miR-182 和 miR-221/222）、细胞增殖（例如 miR-221/222、miR-17/92、miR-21、miR-301a、miR-155、miR-181b、miR-182、miR-214、miR-20b、miR-29a、miR-196、miR-199a-3p、miR-210、miR-301a、miR-375、miR-378-3p 和 miR-489）和血管生成（例如 miR-9、miR-17/92 簇、miR-93 和 miR-210）。特别是，在这里，我们考虑了基于 miRNA 的治疗方法，以总结其在临床实践中潜在治疗用途的证据。因此，miRNA 模拟物（即 miRNA 的替代物和恢复物）和抑制疗法（例如反义寡核苷酸（AMO）、抗 miRNA 寡核苷酸（antagomiRs）或反义寡核苷酸（ASOs）：胆固醇结合的抗 miRNA 和锁核酸（LNA））、miRNA 海绵、纳米颗粒（NPs）、多靶抗 mirna 反义寡核苷酸技术（MTg-AMOs）和人工 miRNA（amiRNAs）在本文中尽可能多地被指出。
